(Immuno)proteasomes as therapeutic target in acute leukemia

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloos, Jacqueline, Roeten, Margot SF, Franke, Niels E, van Meerloo, Johan, Zweegman, Sonja, Kaspers, Gertjan JL, Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/
https://www.ncbi.nlm.nih.gov/pubmed/29071527
http://dx.doi.org/10.1007/s10555-017-9699-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/
https://www.ncbi.nlm.nih.gov/pubmed/29071527
http://dx.doi.org/10.1007/s10555-017-9699-4

Ejemplares similares